Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daclatasvir
- Development stage
- Phase 4
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Daclatasvir is a direct-acting antiviral agent used in combination with other medications, such as sofosbuvir (with or without ribavirin), for the treatment of chronic hepatitis C virus (HCV) infection, particularly genotypes 1 and 3. It was developed as the first drug to demonstrate safety and efficacy in treating HCV genotype 3 without interferon or ribavirin. Daclatasvir acts by inhibiting the nonstructural protein 5A (NS5A), an essential component of the HCV replication complex. By binding to NS5A, daclatasvir disrupts viral RNA replication and virion assembly, leading to decreased serum HCV RNA levels[1][3][6]. The drug is administered orally and is primarily cleared by the liver.
- Brand names
- Daklinza
- Other names
- daclatasvir dihydrochloride
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on daclatasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daclatasvir.